Globe News Wire
13 Jan 2026, 18:00 UTC · 35w ago
Verdict
Headline leans bullish. We score JNJ +0.60 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The systemic lupus erythematosus (SLE) market is projected to grow at a CAGR of 9.4% from 2025 to 2034.
More positive than 97% of claims this week
Biogen's Litifilimab is currently in two Phase III clinical trials for SLE, with topline results anticipated by the end of 2026.
Continue reading
5 related stories
GlobeNewsWire
33m ago
Newsfile Corp
3h ago
More positive than 70% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 92% of claims this week
The SLE competitive landscape includes a robust pipeline of mid- and late-stage therapies from major pharmas including Johnson & Johnson, Novartis, Idorsia, Viatris, and Kyowa Kirin.
So whatA strong, diversified pipeline indicates impending competitive dynamics and potential market share fragmentation, driving investor attention toward the SLE therapeutic area.
More positive than 85% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The company has a promising investigational therapy, nipocalimab, in a growing market.
More positive than 70% of ticker scores this week
The company has an investigational therapy, KK-4277, for the SLE market.
More positive than 70% of ticker scores this week
The company has multiple therapies, including ianalumab and Rapcabtagene autoleucel, in the SLE pipeline.
More positive than 70% of ticker scores this week
The company is evaluating litifilimab in two Phase III clinical studies for SLE.
More positive than 70% of ticker scores this week
The company is developing cenerimod for the SLE market.
More positive than 70% of ticker scores this week
The company is co-developing litifilimab for the SLE market.
More positive than 70% of ticker scores this week
The company is developing cenerimod for the SLE market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 78% of relationship scores this week
[mutual] Idorsia and Viatris are joint developers of the therapy Cenerimod.
More positive than 39% of relationship scores this week
[mutual] Both companies are developing targeted therapies for the systemic lupus erythematosus market.
More positive than 39% of relationship scores this week
[mutual] Both companies are developing targeted therapies for the systemic lupus erythematosus market.
More positive than 39% of relationship scores this week
[mutual] Both companies are developing targeted therapies for the systemic lupus erythematosus market.
More positive than 39% of relationship scores this week
[mutual] Both companies are developing targeted therapies for the systemic lupus erythematosus market.
+30.0%
Price agrees with the score
$272.58 vs $209.72 close before publication (Jan 12) · not market-adjusted
JNJ chart →
